New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

The Indiana Family and Social Service Administration’s Office of Medicaid Policy and Planning estimates that 5% to 20% of eligible members would be prescribed weight-loss medications.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Lazard, Inc. LAZ is “really inexpensive,” the “Mad Money” host said. On Dec. 20, Keefe, Bruyette & Woods analyst Aidan Hall ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

A new quick-and-easy nasal swab test for kids can diagnose the specific immune system drivers behind their asthma, ...

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep ...

Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.